GlycoMimetics reports $47.9M cash; Phase 3 uproleselan trial continues to final events in H1 2024

CRESCENT BIOPHARMA, INC.

Cash and equivalents $47.9M at Dec 31, 2022; raised $28.7M net from ATM in Q1 2023.
R&D expenses fell to $5.9M in Q4 2022 from $12.9M in Q4 2021; full-year R&D $28.4M vs $47.5M.
DMC recommended Phase 3 uproleselan trial continue after interim utility analysis; final OS events expected H1 2024.
Appointed Edwin Rock as CMO, Bruce Johnson as CCO, and Chinmaya Rath as CBO in 2022-2023.
Cash runway projected to fund operations to end of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CRESCENT BIOPHARMA, INC. reported financial results for quarter and year ended December 31, 2022.

Period: quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-004866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.